Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director | June 10, 2026 | June 12, 2026 |
| Gamida Cell Ltd.GMDA · Entity 94655 | Director · President and CEO | October 19, 2023 | October 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2036-06-10 | Direct | 50,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Disposed 50,500 · Balance 50,500 F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Ms. Jenkins' continuous service with the Issuer from the grant date through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Ms. Jenkins' continuous service with the Issuer from the grant date through the applicable vesting date.
Gamida Cell Ltd.
Report date October 19, 2023 · Filed October 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 375,142 |
Reported balance
After 2023-10-19 transaction · row 1
1 source rowRow 1 · 2023-10-19 · Grant · Acquired 109,013 · Balance 375,142 F1: The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023. F2: Represents an RSU award, which vested or shall vest with respect to 33% of the RSUs, on each of August 8, 2023 and August 8, 2024, respectively, and with respect to 34% of the RSUs, on August 8, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2033-10-18 | Direct | 217,954 |
Reported balance
After 2023-10-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-10-19 · Grant · Acquired 217,954 · Balance 217,954 F3: The option grant was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023. F4: 33% of the shares subject to the option award vested or shall vest on each of August 8, 2023 and August 8, 2024, respectively, and 34% of the shares subject to the option award shall vest on August 8, 2025, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023.
F2: Represents an RSU award, which vested or shall vest with respect to 33% of the RSUs, on each of August 8, 2023 and August 8, 2024, respectively, and with respect to 34% of the RSUs, on August 8, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.
F3: The option grant was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023.
F4: 33% of the shares subject to the option award vested or shall vest on each of August 8, 2023 and August 8, 2024, respectively, and 34% of the shares subject to the option award shall vest on August 8, 2025, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 15:42 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,500 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001214659-26-007397 · marketforms-73383.xml · derivative · entry 1 Jenkins Abigail L. · CIK 0001947032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,500 Underlying: Common Stock · 50,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Ms. Jenkins' continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 17:59 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 42,000 | $3.41 Strike: $3.41 | $143,220.00 |
DisclosureSEC source: 0001214659-25-009121 · marketforms-69481.xml · derivative · entry 1 Jenkins Abigail L. · CIK 0001947032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 11, 2026, subject to Ms. Jenkins' continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| May 10, 2024 Filed May 13, 2024 17:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 57,000 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001214659-24-008873 · marketforms-65565.xml · derivative · entry 1 Jenkins Abigail L. · CIK 0001947032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2034-05-10 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on May 10, 2025. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 16:40 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantEmployee Share Option (Right to Buy) · Derivative | 217,954 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-053269 · doc4.xml · derivative · entry 2 Jenkins Abigail L. · CIK 0001947032 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,954 Underlying: Ordinary Shares · 217,954 shares Expires 2033-10-18 F3 · date: The option grant was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023. F4 · derivative.exercise_date: 33% of the shares subject to the option award vested or shall vest on each of August 8, 2023 and August 8, 2024, respectively, and 34% of the shares subject to the option award shall vest on August 8, 2025, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 16:40 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 109,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-053269 · doc4.xml · nonDerivative · entry 1 Jenkins Abigail L. · CIK 0001947032 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,142 F1 · date: The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023. F2 · shares: Represents an RSU award, which vested or shall vest with respect to 33% of the RSUs, on each of August 8, 2023 and August 8, 2024, respectively, and with respect to 34% of the RSUs, on August 8, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 16:34 UTC Amendment | Gamida Cell Ltd. GMDA · Entity 94655 | GrantEmployee Share Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-053258 · doc4a.xml · derivative · entry 2 Jenkins Abigail L. · CIK 0001947032 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Ordinary Shares · 1,000,000 shares Expires 2033-10-18 F3 · date: The option grant was approved by the Board of Directors of the Issuer on September 19, 2022, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023. F4 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award vested on September 19, 2023, and one twelfth (1/12th) of the remaining shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 16:34 UTC Amendment | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-053258 · doc4a.xml · nonDerivative · entry 1 Jenkins Abigail L. · CIK 0001947032 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,129 F1 · date: The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on September 19, 2022, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023. F2 · shares: Represents an RSU award, which vested or shall vest with respect to 33% of the RSUs, on each of September 19, 2023 and September 19, 2024, respectively, and with respect to 34% of the RSUs, on September 19, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 16:19 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | PurchaseOrdinary Shares | 16,129 | $1.55 | $24,999.95 |
DisclosureSEC source: 0001209191-22-052218 · doc4.xml · nonDerivative · entry 1 Jenkins Abigail L. · CIK 0001947032 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,129 F1 · price: The reporting person purchased ordinary shares of the Issuer at a price of $1.55 per share in an underwritten public offering by the Issuer, which closed on September 30, 2022. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 16:10 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-22-050708 · doc4.xml · derivative · entry 2 Jenkins Abigail L. · CIK 0001947032 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Ordinary Shares · 1,000,000 shares Expires 2032-09-18 F2 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on September 19, 2023, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 16:10 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050708 · doc4.xml · nonDerivative · entry 1 Jenkins Abigail L. · CIK 0001947032 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 F1 · shares: Represents a restricted stock unit ("RSU") award, which shall vest with respect to 33% of the RSUs, on each of September 19, 2023 and September 19, 2024, respectively, and with respect to 34% of the RSUs, on September 19, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.